Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AIM | AIM ImmunoTech Inc.

Index- P/E- EPS (ttm)-0.40 Insider Own0.80% Shs Outstand48.41M Perf Week-7.63%
Market Cap29.35M Forward P/E- EPS next Y-0.45 Insider Trans10.86% Shs Float44.56M Perf Month-6.79%
Income-19.30M PEG- EPS next Q-0.11 Inst Own12.30% Short Float / Ratio1.10% / 3.41 Perf Quarter10.20%
Sales0.20M P/S146.73 EPS this Y-0.20% Inst Trans-3.54% Short Interest0.49M Perf Half Y30.16%
Book/sh0.61 P/B0.94 EPS next Y-15.40% ROA-49.00% Target Price3.83 Perf Year-8.99%
Cash/sh0.55 P/C1.03 EPS next 5Y25.00% ROE-53.90% 52W Range0.29 - 0.84 Perf YTD83.62%
Dividend- P/FCF- EPS past 5Y49.80% ROI-52.70% 52W High-31.49% Beta-0.14
Dividend %- Quick Ratio10.00 Sales past 5Y-20.20% Gross Margin- 52W Low96.80% ATR0.05
Employees22 Current Ratio10.00 Sales Q/Q40.00% Oper. Margin- RSI (14)41.33 Volatility5.72% 7.53%
OptionableNo Debt/Eq0.00 EPS Q/Q-0.40% Profit Margin- Rel Volume0.60 Prev Close0.61
ShortableYes LT Debt/Eq0.00 EarningsAug 15 BMO Payout- Avg Volume144.16K Price0.57
Recom2.00 SMA20-9.09% SMA50-8.99% SMA2009.72% Volume85,983 Change-5.67%
Sep-11-23 01:00PM
Sep-05-23 09:05AM
Aug-23-23 08:00AM
Aug-15-23 06:45AM
Aug-09-23 09:05AM
08:05AM Loading…
Aug-08-23 08:05AM
Jul-18-23 07:30PM
Jul-10-23 08:05AM
Jul-05-23 08:35AM
Jun-27-23 11:16AM
Jun-14-23 08:45AM
Jun-12-23 08:45AM
Jun-07-23 07:11PM
08:45AM Loading…
May-15-23 08:45AM
May-09-23 08:50AM
Apr-20-23 03:56PM
Apr-12-23 08:35AM
Apr-10-23 07:30AM
Apr-04-23 08:45AM
Apr-03-23 06:30AM
Mar-30-23 08:45AM
Mar-27-23 09:05AM
Mar-16-23 08:45AM
07:00AM Loading…
Mar-08-23 08:45AM
Mar-06-23 08:45AM
Feb-28-23 08:45AM
Feb-17-23 08:55AM
Jan-17-23 08:45AM
Jan-11-23 01:00PM
Jan-09-23 08:05AM
Jan-05-23 08:45AM
Dec-12-22 09:00AM
Dec-08-22 08:05AM
Dec-02-22 10:45AM
Nov-15-22 07:00AM
Nov-14-22 07:00AM
Nov-09-22 09:00AM
Nov-03-22 12:34PM
Nov-02-22 07:05AM
Nov-01-22 05:19PM
Oct-31-22 07:30AM
Oct-26-22 05:12PM
Oct-24-22 08:30AM
Oct-13-22 10:32AM
Oct-12-22 04:32PM
Sep-21-22 08:45AM
Sep-19-22 08:05AM
Sep-07-22 07:25AM
Sep-06-22 07:30AM
Aug-30-22 07:30AM
Aug-18-22 09:05AM
Aug-16-22 04:05PM
Aug-15-22 04:05PM
Jul-28-22 09:10AM
Jul-21-22 12:26PM
Jul-20-22 08:05AM
Jul-18-22 08:00AM
Jul-14-22 08:05AM
Jun-21-22 08:35AM
Jun-13-22 08:05AM
May-19-22 08:00AM
May-18-22 08:00AM
May-16-22 07:05AM
May-12-22 08:05AM
Apr-21-22 08:05AM
Apr-12-22 07:47AM
Apr-11-22 09:20AM
Apr-04-22 06:26PM
Mar-31-22 04:05PM
Mar-30-22 07:00AM
Mar-29-22 10:17PM
Mar-28-22 07:35AM
Mar-24-22 10:10AM
Mar-23-22 08:05AM
Mar-21-22 08:00AM
Mar-16-22 07:05AM
Mar-09-22 07:35AM
Mar-08-22 01:59PM
Mar-07-22 08:05AM
Mar-03-22 08:35AM
Jan-26-22 08:05AM
Jan-24-22 08:00AM
Jan-19-22 08:35AM
Jan-12-22 10:35AM
Dec-09-21 07:20AM
Dec-06-21 07:25AM
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Equels Thomas KCEO & PresidentAug 25Buy0.678,2225,501584,160Aug 25 02:26 PM
Equels Thomas KCEO & PresidentAug 24Buy0.6714,99310,000575,938Aug 24 01:52 PM
Equels Thomas KCEO & PresidentJul 17Buy0.5916,95010,000560,945Jul 17 07:20 PM
Equels Thomas KCEO & PresidentJan 03Buy0.31161,29150,000543,995Jan 04 07:30 AM
Rodino Peter W IIICOO, Secretary, Gen. CounselJan 03Buy0.3180,64625,000143,839Jan 04 07:30 AM
APPELROUTH STEWARTDirectorJan 03Buy0.3180,64625,000217,063Jan 04 07:30 AM